Prostate-specific antigen: current status
- PMID: 11321246
Prostate-specific antigen: current status
Abstract
PSA is the most important of all tumor markers because it has significant applications in all aspects of the management of men with prostatic disease. Certainly, the most important utilization of PSA is for early detection of this most ubiquitous of all human neoplasms. In this article the authors describe the molecular forms of PSA and their characteristics, the factors influencing values of serum concentration of PSA, the problems of screening, and particularly the possibility to use PSA for detection of prostate carcinoma. A big problem in prostate carcinoma detection is the low specificity of PSA at the concentrations between 4-10 ng/ml, the so-called diagnostic gray zone, where the incidence of prostate carcinoma is only 25%. The authors evaluate the methods which make it possible to increase the sensitivity and/or specificity of PSA detection, such as PSA density, PSA density of the transition zone, PSA velocity, PSA doubling time, age-specific PSA, free PSA and, prospectively, the use of the RT-PCR technique.
Similar articles
-
Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.Cancer. 2005 Jan 15;103(2):242-50. doi: 10.1002/cncr.20739. Cancer. 2005. PMID: 15578715
-
Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.J Urol. 2002 Jan;167(1):103-11. J Urol. 2002. PMID: 11743285
-
[Prostate-specific antigen].Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2528-31. Tidsskr Nor Laegeforen. 2000. PMID: 11070990 Review. Norwegian.
-
Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.J Urol. 2002 Jan;167(1):97-102. J Urol. 2002. PMID: 11743284
-
[Advancements in PSA-based screening for prostate cancer].Rinsho Byori. 2004 Jul;52(7):611-7. Rinsho Byori. 2004. PMID: 15344561 Review. Japanese.
Cited by
-
The Marker State Space (MSS) method for classifying clinical samples.PLoS One. 2013 Jun 4;8(6):e65905. doi: 10.1371/journal.pone.0065905. Print 2013. PLoS One. 2013. PMID: 23750276 Free PMC article.
-
Role of Imaging in Prostate Cancer.PET Clin. 2009 Apr 1;4(2):135-8. doi: 10.1016/j.cpet.2009.05.003. PET Clin. 2009. PMID: 20161047 Free PMC article. No abstract available.
-
A piece in prostate cancer puzzle: Future perspective of novel molecular signatures.Saudi J Biol Sci. 2020 Apr;27(4):1148-1154. doi: 10.1016/j.sjbs.2020.02.003. Epub 2020 Feb 10. Saudi J Biol Sci. 2020. PMID: 32256177 Free PMC article. Review.
-
Patented prostate cancer biomarkers.Nat Rev Urol. 2012 Aug;9(8):464-72. doi: 10.1038/nrurol.2012.130. Epub 2012 Jul 3. Nat Rev Urol. 2012. PMID: 22750955 Review.
-
Hemoglobin-Albumin-Lymphocyte-Platelet (HALP) Score as a Predictive Value of Incidental Prostate Cancer for Patients Going for Transurethral Resection of the Prostate (TURP): A Single-Center Study.Cureus. 2024 Apr 6;16(4):e57736. doi: 10.7759/cureus.57736. eCollection 2024 Apr. Cureus. 2024. PMID: 38716011 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous